Navigation Links
Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
Date:5/20/2011

ing the time until pain worsens.  XGEVA also offers the ease of every four weeks subcutaneous injection and no requirement for dose adjustment for changes in renal function. XGEVA has the potential to make a meaningful difference for patients with advanced cancer and their healthcare providers."

The CHMP positive opinion is based on three pivotal, Phase 3 head-to-head trials that evaluated the effectiveness of XGEVA versus Zometa® (zoledronic acid) at delaying SREs. The clinical program for XGEVA spanned more than 50 tumor types in over 5,700 patients. In the SRE trials, XGEVA demonstrated a clinically meaningful improvement in preventing SREs compared to Zometa.

Specifically, in patients with breast or prostate cancer and bone metastases, XGEVA was superior to Zometa in reducing the risk of SREs. In patients with bone metastases due to other solid tumors or multiple myeloma, XGEVA was non-inferior to Zometa in reducing the risk of SREs. In an integrated analysis of all three studies XGEVA was superior to Zometa in delaying time to first on-study SRE by 17 percent or 8.2 months (median time to first skeletal related event of 27.6 months for XGEVA and 19.4 months for Zometa, p <0.0001). In this analysis, XGEVA was also superior to Zometa in delaying time to first-and-subsequent on-study SRE by 18 percent (p<0.0001).

In patients with mild or no pain at baseline, time to worsening pain was delayed for XGEVA compared to Zometa (198 versus 143 days) (p=0.0002).  The time to pain improvement was similar for XGEVA and Zometa.

In these double-blind trials, XGEVA was administered every four weeks as a 120 mg subcutaneous injection, versus Zometa delivered every four weeks via a 15-minute intravenous infusion, with adjustments for kidney function per the requirements of the Zometa prescribing information. XGEVA was not associated with renal toxicity or acute phase reactions, both well known side effects of Zometa treatment. '/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Sept. 3, 2015 OticPharma, Ltd., a privately ... for ear, nose, and throat (ENT) disorders, today announced ... complex to be the location of its new U.S. ... of September and will have office locations in both ... OticPharma, Inc. 19900 MacArthur Blvd., Suite 550 ...
(Date:9/2/2015)... , Sept. 2, 2015 This report ... the current and future prospects of the global ... health and assists medical practitioners in deciding the ... progression during treatment. Multi-parameter patient monitoring is effective ... disease. Geriatric population is observed to be at ...
(Date:9/2/2015)... , Sept. 2, 2015 About ... is used to treat an unruptured and ruptured ... wall). The treatment is either known as an ... the endovascular coil blocks the blood flow in ... performed under general anaesthesia by an interventional neuroradiologist ...
Breaking Medicine Technology:OticPharma Establishes U.S. Headquarters in Orange County, California 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Multi-parameter Patient Monitoring Equipment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... Sept. 19 Immtech Pharmaceuticals,Inc. (Amex: ... Food and Drug Administration,(FDA) has granted Orphan ... African Trypanosomiasis (HAT), also known as African,sleeping ... numerous,financial and regulatory benefits during pafuramidine,s development,including ...
... Both Cultures and Spores of the ... CHICAGO, Sept. 19 Targanta Therapeutics Corporation,today released ... activity of its,lead antibiotic drug candidate, oritavancin, to ... are being presented today,at the 47th Annual Interscience ...
Cached Medicine Technology:US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 2US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness 3Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria 2Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria 3
(Date:9/3/2015)... ... 2015 , ... Global Vision , the world leader in the development ... print and artwork inspection solutions, ScanProof and ArtProof at Packaging Innovations 2015. ... London, booth #F33 , Be the first to get a sneak peek of Intelligent ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers ... Foundation with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free ... friends and family to enjoy Thanksgiving and Christmas with an extra big smile. ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... A scar is an unavoidable result of ... near-miraculous example of the body's ability to heal itself. The appearance of a scar is ... the individual's age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their ...
(Date:9/3/2015)... ... 03, 2015 , ... Representatives with State Farm Agent EJ ... Mississippi Gulf Babypalooza on September 19, 2015. , “We will be providing information ... beyond. We will be discussing setting up college funds, offering information specific to ...
(Date:9/3/2015)... Santa Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases ... annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While ... increases to six of every 10 men by age 65, according to the American ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
... YORK The Max Cure Foundation and the Samuel Waxman Cancer ... cancer research. With that goal in mind, the two Foundations ... G. Van Meir, Ph.D., of Emory University School of Medicine ... using a small molecule that will target the Ewing sarcoma ...
... July 1 issue of the journal SLEEP shows that ... vigor, fatigue and mood in collegiate basketball players. The ... the athletic performance of actively competing athletes. Results ... time per night during sleep extension was 110.9 minutes ...
... awarded $2.4 million to Allina Hospitals & Clinics to ... pain management for patients at Abbott Northwestern Hospital in ... Health and Healing and the Center for Healthcare Innovation ... study. "Integrative medicine emphasizes a full range of ...
... the Salk Institute for Biological Studies have found clues to ... The protein, p53, can cause cells to stop dividing or ... damage, and it is responsible for much of the tissue ... such as the ones commonly used for cancer therapy. The ...
... the foot just before ground contact during running and walking ... a new study published by a University of Georgia kinesiology ... the June online edition of the American Journal of ... of repetitive ankle sprains demonstrated lower clearance heights between their ...
... June 30 (HealthDay News) -- Women diagnosed with breast cancer ... rates than women who just have breast cancer, according to ... cancer but no chronic illness, those who had conditions such ... or lower survival rate, the study authors reported in the ...
Cached Medicine News:Health News:Targeting the Ewing sarcoma family of tumors 2Health News:Extended sleep improves the athletic performance of collegiate basketball players 2Health News:Extended sleep improves the athletic performance of collegiate basketball players 3Health News:Allina receives NIH grant to study real world usage of integrative therapies 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 2Health News:The genome guardian's dimmer switch: Regulating p53 is a matter of life or death 3Health News:Foot positioning during walking and running may influence ankle sprains 2Health News:Breast Cancer Plus Other Health Issues Linked to Worse Outcomes 2
Transcranial vascular DWL doppler....
... 9100HS is a powerful automated system capable ... Choose from 6 user-programmable test protocols to ... exam. Any tests not included in the ... be handled using the Doppler, PVR and ...
The CD Horizon M8 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... The VasoGuard from VIASYS Neurocare ... forward in physiologic vascular diagnosis. Exceptional ... and system reliability. , ,VasoGuard delivers ... The unique QuickConnect arm for cuff ...
Medicine Products: